Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

488 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Hurst JR, et al. Among authors: anzueto a. N Engl J Med. 2010 Sep 16;363(12):1128-38. doi: 10.1056/NEJMoa0909883. N Engl J Med. 2010. PMID: 20843247 Free article.
Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.
Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, Celli BR, Edwards LD, Locantore N, Macnee W, Tal-Singer R, Lomas DA; ECLIPSE Investigators. Sin DD, et al. Am J Respir Crit Care Med. 2011 May 1;183(9):1187-92. doi: 10.1164/rccm.201008-1220OC. Epub 2011 Jan 7. Am J Respir Crit Care Med. 2011. PMID: 21216880 Free PMC article. Clinical Trial.
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease.
Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, Calverley PM, Tal-Singer R, Agusti A, Coxson HO, Lomas DA, MacNee W, Rennard S, Silverman EK, Crim CC, Yates J, Wouters EF; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Spruit MA, et al. J Am Med Dir Assoc. 2012 Mar;13(3):291-7. doi: 10.1016/j.jamda.2011.06.009. Epub 2011 Jul 21. J Am Med Dir Assoc. 2012. PMID: 21778120
Changes in forced expiratory volume in 1 second over time in COPD.
Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI; ECLIPSE Investigators. Vestbo J, et al. N Engl J Med. 2011 Sep 29;365(13):1184-92. doi: 10.1056/NEJMoa1105482. Epub 2011 Sep 26. N Engl J Med. 2011. PMID: 21991892 Free article.
CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes.
Romme EA, Murchison JT, Edwards LD, van Beek E Jr, Murchison DM, Rutten EP, Smeenk FW, Williams MC, Wouters EF, MacNee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators. Romme EA, et al. J Bone Miner Res. 2013 Jun;28(6):1369-77. doi: 10.1002/jbmr.1873. J Bone Miner Res. 2013. PMID: 23361992 Free article. Clinical Trial.
Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.
Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators. Cheng DT, et al. Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57. doi: 10.1164/rccm.201302-0247OC. Am J Respir Crit Care Med. 2013. PMID: 23947473
Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis.
Cho MH, McDonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, Demeo DL, Sylvia JS, Ziniti J, Laird NM, Lange C, Litonjua AA, Sparrow D, Casaburi R, Barr RG, Regan EA, Make BJ, Hokanson JE, Lutz S, Dudenkov TM, Farzadegan H, Hetmanski JB, Tal-Singer R, Lomas DA, Bakke P, Gulsvik A, Crapo JD, Silverman EK, Beaty TH; NETT Genetics, ICGN, ECLIPSE and COPDGene Investigators. Cho MH, et al. Lancet Respir Med. 2014 Mar;2(3):214-25. doi: 10.1016/S2213-2600(14)70002-5. Epub 2014 Feb 7. Lancet Respir Med. 2014. PMID: 24621683 Free PMC article.
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A. Decramer M, et al. Among authors: anzueto a. Lancet Respir Med. 2014 Jun;2(6):472-86. doi: 10.1016/S2213-2600(14)70065-7. Epub 2014 May 14. Lancet Respir Med. 2014. PMID: 24835833 Clinical Trial.
488 results